<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01144377</url>
  </required_header>
  <id_info>
    <org_study_id>11953</org_study_id>
    <secondary_id>I2M-MC-GSDB</secondary_id>
    <nct_id>NCT01144377</nct_id>
  </id_info>
  <brief_title>A Study of LY2541546 in Women With Low Bone Mineral Density</brief_title>
  <official_title>A Phase 2 Randomized Study of LY2541546 Versus Placebo in Postmenopausal Women With Low Bone Mineral Density: An Evaluation of the Dose Response Relationship Using Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study include evaluating the dose response of LY2541546 using
      bone mineral density (BMD) change from baseline as compared to placebo and evaluating the
      overall safety and tolerability of LY2541546 following multiple subcutaneous administrations
      in postmenopausal (PMP) women with low BMD. Following the last dose of study drug,
      participants will be able to participate in a 12 month extension to collect additional safety
      and efficacy data (no further treatment will be administered during this extension).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD)</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>Lumbar spine bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).
Least squares (LS) mean values were determined using a mixed-effects model repeated-measures (MMRM) analysis of covariance.
Factors in the model included treatment, time and the interaction of treatment by time as fixed effects, and baseline lumbar spine BMD as a covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12, 24, and 64 Weeks in Lumbar Spine Bone Mineral Density (BMD)</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks and 64 weeks</time_frame>
    <description>Lumbar spine bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).
Least squares (LS) mean values were determined using a mixed-effects model repeated-measures (MMRM) analysis of covariance.
Factors in the model included treatment, time and the interaction of treatment by time as fixed effects, and baseline lumbar spine BMD as a covariate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24, 52, and 64 Weeks in Proximal Femur Bone Mineral Density (BMD)</measure>
    <time_frame>Baseline, 24 weeks and 52 weeks and 64 weeks</time_frame>
    <description>Femoral neck and total hip bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).
Least squares (LS) mean values were determined using a mixed-effects model repeated-measures (MMRM) analysis of covariance.
Factors in the model included treatment, time and the interaction of treatment by time as fixed effects, and baseline BMD as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint in Wrist Bone Mineral Density (BMD)</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>Total radius of the wrist bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).
Least squares (LS) mean values were determined using a 1-factor analysis of covariance model with treatment group as the main effect and baseline BMD as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint in Bone-specific Alkaline Phosphatase (BSAP)</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint in Serum Type I Collagen Fragment (CTx)</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint in Osteocalcin</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52 Week Endpoint in Serum N-terminal Extension Propeptide of Type I Collagen (P1NP)</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>180 mg LY2541546 Q4W + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2541546: 180 milligrams (mg) administered subcutaneously every 4 weeks (Q4W) for 52 weeks.
Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 mg LY2541546 Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2541546: 180 milligrams (mg) administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>270 mg LY2541546 Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2541546: 270 milligrams (mg) LY2541546 administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>270 mg LY2541546 Q12W + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2541546: 270 milligrams (mg) administered subcutaneously every 12 weeks (Q12W) for 52 weeks.
Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2541546</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>180 mg LY2541546 Q4W + Placebo</arm_group_label>
    <arm_group_label>180 mg LY2541546 Q2W</arm_group_label>
    <arm_group_label>270 mg LY2541546 Q2W</arm_group_label>
    <arm_group_label>270 mg LY2541546 Q12W + Placebo</arm_group_label>
    <other_name>Blosozumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>180 mg LY2541546 Q4W + Placebo</arm_group_label>
    <arm_group_label>270 mg LY2541546 Q12W + Placebo</arm_group_label>
    <arm_group_label>Placebo Comparator Q2W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory, postmenopausal women, inclusive.

          -  Have low bone mineral density (BMD), defined as a T-score or equivalent BMD absolute
             value (grams/square centimeter [g/cm^2]) for the lumbar spine of between -3.5 and
             -2.0, inclusive.

          -  Without language barrier, reliable, and willing to make themselves available for the
             duration of the study and to follow study procedures.

          -  Willing to take study drug and daily supplements (calcium and Vitamin D).

          -  Normal laboratory tests or laboratory test results determined not clinically
             significant by the investigator. Serum phosphate and serum calcium must be within
             normal limits, and platelet level greater than 100,000 cubic millimeters (mm^3).

        Exclusion Criteria:

          -  Have received treatment with any of the following medications more recently than 3
             months prior to screening Androgen, Calcitonin, Estrogen (including over the counter
             preparations known to have estrogenic activity), Progestin (including over the counter
             preparations known to have progestogenic activity), selective estrogen receptor
             modulators (SERMs) (Raloxifene, Tamoxifen, Toremifene, Clomiphene), or Tibolone.

          -  Have previously used or currently use denosumab, parathyroid hormone (PTH) and/or PTH
             analogs, strontium ranelate, or parenteral formulations of bisphosphonates.

          -  Have received treatment with any oral bisphosphonate within the last year.

          -  Have received therapeutic doses of systemic corticosteroids for more than one month
             during the 6 months prior to screening.

          -  Have received therapeutic doses of fluorides (20 milligrams per day) for more than 3
             months during the last 3 years, or for more than a total of 2 years, or any within the
             last 6 months.

          -  Have severe Vitamin D deficiency defined as 25-hydroxyvitamin D less than &lt;9.2
             nanograms per milliliter (ng/mL) [23 nanomoles per liter (nmol/L)] at screening. If
             the serum 25-hydroxy-vitamin D level at screening is less than or equal to 9.2 ng/mL
             and &lt;20 ng/mL, participants will receive a loading dose of Vitamin D (at a dose of
             approximately 100,000 international units (IU) given orally) prior to enrollment.

          -  Have any known bone disorder other than low BMD or osteoporosis.

          -  Have a history of osteoporotic fractures, including known prevalent vertebral fracture
             or evidence of prevalent vertebral fracture on screening spine X-ray or dual-energy
             x-ray absorptiometry (DXA), or are considered to be at high risk for fracture.

          -  Presence of any abnormality (such as artifacts or osteophytes) that would confound DXA
             evaluation of lumbar vertebrae in the L-1 through L-4 region.

          -  Have a history of Bell's palsy, other cranial nerve disorders, or have a history of
             Temporomandibular Joint and Muscle Disorders (TMJDs).

          -  Have any history of cancer within the previous 5 years, except for excised superficial
             lesions such as basal cell carcinoma and squamous cell carcinoma of the skin.

          -  Have history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             constituting a risk when taking the study medication or of interfering with the
             interpretation of data.

          -  Have acute or chronic liver disease ([bilirubin &gt;34 micromoles per liter (µmol/L) or
             &gt;2.0 milligrams per deciliter (mg/dL), alanine transaminase [ALT/SGPT] &gt;100 units per
             liter (U/L), or alkaline phosphatase &gt;300 U/L)].

          -  Have impaired kidney function serum creatinine &gt;135 µmol/L or &gt;2.0 mg/dL.

          -  Have known allergy to LY2541546, any of diluents or excipients of LY2541546, or
             significant allergy to any other monoclonal antibody.

          -  History of excessive consumption of alcohol or abuse of drugs within the last year.

          -  Have poor medical condition or psychiatric risks for treatment with an investigational
             drug.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tallinn</city>
        <zip>10128</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagano</city>
        <zip>386-0493</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>166-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vilnius</city>
        <zip>10323</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Japan</country>
    <country>Lithuania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2010</study_first_posted>
  <results_first_submitted>September 27, 2017</results_first_submitted>
  <results_first_submitted_qc>October 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 4, 2017</results_first_posted>
  <disposition_first_submitted>September 18, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>September 18, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 25, 2012</disposition_first_posted>
  <last_update_submitted>October 28, 2017</last_update_submitted>
  <last_update_submitted_qc>October 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>After exposure to study medication for the 52 week treatment phase, participants entered a 12 week non-treatment safety follow-up period with the option of staying in the non-treatment safety follow-up period for an additional 40 weeks (for a total of 52 weeks follow-up for the main study participants only).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>180 mg LY2541546 Q4W + Placebo</title>
          <description>LY2541546 + Placebo: 180 milligrams (mg) LY2541546 administered subcutaneously every 4 weeks (Q4W) for 52 weeks with Placebo administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks. After exposure to study medication for the 52 week treatment phase, participants entered a 12 week non-treatment safety follow-up period with the option of staying in the non-treatment safety follow-up period for an additional 40 weeks (for a total of 52 weeks follow-up for the main study participants only).</description>
        </group>
        <group group_id="P2">
          <title>180 mg LY2541546 Q2W</title>
          <description>LY2541546: 180 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks. After exposure to study medication for the 52 week treatment phase, participants entered a 12 week non-treatment safety follow-up period with the option of staying in the non-treatment safety follow-up period for an additional 40 weeks (for a total of 52 weeks follow-up for the main study participants only).</description>
        </group>
        <group group_id="P3">
          <title>270 mg LY2541546 Q2W</title>
          <description>LY2541546: 270 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks. After exposure to study medication for the 52 week treatment phase, participants entered a 12 week non-treatment safety follow-up period with the option of staying in the non-treatment safety follow-up period for an additional 40 weeks (for a total of 52 weeks follow-up for the main study participants only).</description>
        </group>
        <group group_id="P4">
          <title>270 mg LY2541546 Q12W + Placebo</title>
          <description>LY2541546 + Placebo: 270 mg LY2541546 administered subcutaneously every 12 weeks (Q12W) with Placebo administered subcutaneously every 2 weeks when LY2541546 is not administered for 52 weeks. After exposure to study medication for the 52 week treatment phase, participants entered a 12 week non-treatment safety follow-up period with the option of staying in the non-treatment safety follow-up period for an additional 40 weeks (for a total of 52 weeks follow-up for the main study participants only).</description>
        </group>
        <group group_id="P5">
          <title>Placebo Q2W</title>
          <description>Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks. After exposure to study medication for the 52 week treatment phase, participants entered a 12 week non-treatment safety follow-up period with the option of staying in the non-treatment safety follow-up period (for an additional 40 weeks for a total of 52 weeks follow-up for the main study participants only).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>52 Week Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12 Week Safety Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26">Of the 26 participants who completed this Period, 22 continued to the Optional 40 Week follow-up.</participants>
                <participants group_id="P2" count="29">Of the 29 participants who completed this Period, 25 continued to the Optional 40 Week follow-up.</participants>
                <participants group_id="P3" count="25">Of the 25 participants who completed this Period, 23 continued to the Optional 40 Week follow-up.</participants>
                <participants group_id="P4" count="22">Of the 22 participants who completed this Period, 3 continued to the Optional 40 Week follow-up.</participants>
                <participants group_id="P5" count="34">Of the 34 participants who completed this Period, 23 continued to the Optional 40 Week follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Optional 40 Week Safety Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>180 mg LY2541546 Q4W + Placebo</title>
          <description>LY2541546 + Placebo: 180 milligrams (mg) LY2541546 administered subcutaneously every 4 weeks (Q4W) for 52 weeks with Placebo administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>180 mg LY2541546 Q2W</title>
          <description>LY2541546: 180 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>270 mg LY2541546 Q2W</title>
          <description>LY2541546: 270 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
        </group>
        <group group_id="B4">
          <title>270 mg LY2541546 Q12W + Placebo</title>
          <description>LY2541546 + Placebo: 270 mg LY2541546 administered subcutaneously every 12 weeks (Q12W) with Placebo administered subcutaneously every 2 weeks when LY2541546 is not administered for 52 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Placebo Q2W</title>
          <description>Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="37"/>
            <count group_id="B6" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.78" spread="8.98"/>
                    <measurement group_id="B2" value="64.17" spread="8.20"/>
                    <measurement group_id="B3" value="66.12" spread="7.68"/>
                    <measurement group_id="B4" value="63.56" spread="8.02"/>
                    <measurement group_id="B5" value="65.17" spread="8.91"/>
                    <measurement group_id="B6" value="65.22" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lumbar Spine Bone Mineral Density (Baseline)</title>
          <units>grams/square centimeter (g/cm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.78" spread="0.09"/>
                    <measurement group_id="B2" value="0.78" spread="0.07"/>
                    <measurement group_id="B3" value="0.80" spread="0.09"/>
                    <measurement group_id="B4" value="0.77" spread="0.09"/>
                    <measurement group_id="B5" value="0.78" spread="0.09"/>
                    <measurement group_id="B6" value="0.78" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Femoral Neck Bone Mineral Density (Baseline)</title>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.66" spread="0.15"/>
                    <measurement group_id="B2" value="0.66" spread="0.15"/>
                    <measurement group_id="B3" value="0.69" spread="0.11"/>
                    <measurement group_id="B4" value="0.63" spread="0.11"/>
                    <measurement group_id="B5" value="0.66" spread="0.17"/>
                    <measurement group_id="B6" value="0.66" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Hip Bone Mineral Density (Baseline)</title>
          <units>grams/square centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.75" spread="0.11"/>
                    <measurement group_id="B2" value="0.75" spread="0.13"/>
                    <measurement group_id="B3" value="0.77" spread="0.10"/>
                    <measurement group_id="B4" value="0.73" spread="0.11"/>
                    <measurement group_id="B5" value="0.73" spread="0.14"/>
                    <measurement group_id="B6" value="0.75" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 52 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD)</title>
        <description>Lumbar spine bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).
Least squares (LS) mean values were determined using a mixed-effects model repeated-measures (MMRM) analysis of covariance.
Factors in the model included treatment, time and the interaction of treatment by time as fixed effects, and baseline lumbar spine BMD as a covariate.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline lumbar spine BMD value.</population>
        <group_list>
          <group group_id="O1">
            <title>180 mg LY2541546 Q4W + Placebo</title>
            <description>LY2541546 + Placebo: 180 milligrams (mg) LY2541546 administered subcutaneously every 4 weeks (Q4W) for 52 weeks with Placebo administered every alternate 2 weeks from the LY2541546 dose for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>180 mg LY2541546 Q2W</title>
            <description>LY2541546: 180 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>270 mg LY2541546 Q2W</title>
            <description>LY2541546: 270 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>270 mg LY2541546 Q12W + Placebo</title>
            <description>LY2541546 + Placebo: 270 mg LY2541546 administered subcutaneously every 12 weeks (Q12W) with Placebo administered every 2 weeks when LY2541546 is not administered for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo Q2W</title>
            <description>Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD)</title>
          <description>Lumbar spine bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).
Least squares (LS) mean values were determined using a mixed-effects model repeated-measures (MMRM) analysis of covariance.
Factors in the model included treatment, time and the interaction of treatment by time as fixed effects, and baseline lumbar spine BMD as a covariate.</description>
          <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline lumbar spine BMD value.</population>
          <units>g/cm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.065" lower_limit="0.048" upper_limit="0.082"/>
                    <measurement group_id="O2" value="0.115" lower_limit="0.099" upper_limit="0.131"/>
                    <measurement group_id="O3" value="0.142" lower_limit="0.125" upper_limit="0.158"/>
                    <measurement group_id="O4" value="0.054" lower_limit="0.036" upper_limit="0.073"/>
                    <measurement group_id="O5" value="-0.011" lower_limit="-0.026" upper_limit="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12, 24, and 64 Weeks in Lumbar Spine Bone Mineral Density (BMD)</title>
        <description>Lumbar spine bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).
Least squares (LS) mean values were determined using a mixed-effects model repeated-measures (MMRM) analysis of covariance.
Factors in the model included treatment, time and the interaction of treatment by time as fixed effects, and baseline lumbar spine BMD as a covariate</description>
        <time_frame>Baseline, 12 weeks and 24 weeks and 64 weeks</time_frame>
        <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline lumbar spine BMD value.</population>
        <group_list>
          <group group_id="O1">
            <title>180 mg LY2541546 Q4W + Placebo</title>
            <description>LY2541546 + Placebo: 180 milligrams (mg) LY2541546 administered subcutaneously every 4 weeks (Q4W) for 52 weeks with Placebo administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>180 mg LY2541546 Q2W</title>
            <description>LY2541546: 180 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>270 mg LY2541546 Q2W</title>
            <description>LY2541546: 270 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>270 mg LY2541546 Q12W + Placebo</title>
            <description>LY2541546 + Placebo: 270 mg LY2541546 administered subcutaneously every 12 weeks (Q12W) with Placebo administered subcutaneously every 2 weeks when LY2541546 is not administered for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo Q2W</title>
            <description>Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12, 24, and 64 Weeks in Lumbar Spine Bone Mineral Density (BMD)</title>
          <description>Lumbar spine bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).
Least squares (LS) mean values were determined using a mixed-effects model repeated-measures (MMRM) analysis of covariance.
Factors in the model included treatment, time and the interaction of treatment by time as fixed effects, and baseline lumbar spine BMD as a covariate</description>
          <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline lumbar spine BMD value.</population>
          <units>g/cm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.028" lower_limit="0.020" upper_limit="0.037"/>
                    <measurement group_id="O2" value="0.048" lower_limit="0.039" upper_limit="0.057"/>
                    <measurement group_id="O3" value="0.057" lower_limit="0.048" upper_limit="0.065"/>
                    <measurement group_id="O4" value="0.039" lower_limit="0.029" upper_limit="0.049"/>
                    <measurement group_id="O5" value="-0.007" lower_limit="-0.015" upper_limit="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.049" lower_limit="0.037" upper_limit="0.061"/>
                    <measurement group_id="O2" value="0.083" lower_limit="0.071" upper_limit="0.094"/>
                    <measurement group_id="O3" value="0.098" lower_limit="0.086" upper_limit="0.109"/>
                    <measurement group_id="O4" value="0.048" lower_limit="0.035" upper_limit="0.061"/>
                    <measurement group_id="O5" value="-0.006" lower_limit="-0.016" upper_limit="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046" lower_limit="0.032" upper_limit="0.061"/>
                    <measurement group_id="O2" value="0.098" lower_limit="0.083" upper_limit="0.112"/>
                    <measurement group_id="O3" value="0.135" lower_limit="0.120" upper_limit="0.150"/>
                    <measurement group_id="O4" value="0.046" lower_limit="0.029" upper_limit="0.062"/>
                    <measurement group_id="O5" value="-0.007" lower_limit="-0.020" upper_limit="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24, 52, and 64 Weeks in Proximal Femur Bone Mineral Density (BMD)</title>
        <description>Femoral neck and total hip bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).
Least squares (LS) mean values were determined using a mixed-effects model repeated-measures (MMRM) analysis of covariance.
Factors in the model included treatment, time and the interaction of treatment by time as fixed effects, and baseline BMD as a covariate.</description>
        <time_frame>Baseline, 24 weeks and 52 weeks and 64 weeks</time_frame>
        <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline femoral neck or total hip BMD value.</population>
        <group_list>
          <group group_id="O1">
            <title>180 mg LY2541546 Q4W + Placebo</title>
            <description>LY2541546 + Placebo: 180 milligrams (mg) LY2541546 administered subcutaneously every 4 weeks (Q4W) for 52 weeks with Placebo administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>180 mg LY2541546 Q2W</title>
            <description>LY2541546: 180 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>270 mg LY2541546 Q2W</title>
            <description>LY2541546: 270 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>270 mg LY2541546 Q12W + Placebo</title>
            <description>LY2541546 + Placebo: 270 mg LY2541546 administered subcutaneously every 12 weeks (Q12W) with Placebo administered subcutaneously every 2 weeks when LY2541546 is not administered for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo Q2W</title>
            <description>Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24, 52, and 64 Weeks in Proximal Femur Bone Mineral Density (BMD)</title>
          <description>Femoral neck and total hip bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).
Least squares (LS) mean values were determined using a mixed-effects model repeated-measures (MMRM) analysis of covariance.
Factors in the model included treatment, time and the interaction of treatment by time as fixed effects, and baseline BMD as a covariate.</description>
          <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline femoral neck or total hip BMD value.</population>
          <units>g/cm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Femoral Neck BMD Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" lower_limit="0.002" upper_limit="0.019"/>
                    <measurement group_id="O2" value="0.017" lower_limit="0.009" upper_limit="0.025"/>
                    <measurement group_id="O3" value="0.026" lower_limit="0.018" upper_limit="0.034"/>
                    <measurement group_id="O4" value="0.002" lower_limit="-0.007" upper_limit="0.011"/>
                    <measurement group_id="O5" value="0.002" lower_limit="-0.005" upper_limit="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Hip BMD Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" lower_limit="-0.001" upper_limit="0.014"/>
                    <measurement group_id="O2" value="0.020" lower_limit="0.013" upper_limit="0.027"/>
                    <measurement group_id="O3" value="0.031" lower_limit="0.024" upper_limit="0.039"/>
                    <measurement group_id="O4" value="0.015" lower_limit="0.007" upper_limit="0.023"/>
                    <measurement group_id="O5" value="-0.007" lower_limit="-0.014" upper_limit="-0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral Neck BMD Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" lower_limit="0.010" upper_limit="0.026"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.017" upper_limit="0.033"/>
                    <measurement group_id="O3" value="0.044" lower_limit="0.035" upper_limit="0.052"/>
                    <measurement group_id="O4" value="0.014" lower_limit="0.005" upper_limit="0.024"/>
                    <measurement group_id="O5" value="0.003" lower_limit="-0.005" upper_limit="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Hip BMD Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.017" lower_limit="0.008" upper_limit="0.025"/>
                    <measurement group_id="O2" value="0.032" lower_limit="0.023" upper_limit="0.040"/>
                    <measurement group_id="O3" value="0.051" lower_limit="0.043" upper_limit="0.060"/>
                    <measurement group_id="O4" value="0.019" lower_limit="0.009" upper_limit="0.029"/>
                    <measurement group_id="O5" value="-0.004" lower_limit="-0.012" upper_limit="0.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral Neck BMD Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016" lower_limit="0.007" upper_limit="0.026"/>
                    <measurement group_id="O2" value="0.028" lower_limit="0.019" upper_limit="0.037"/>
                    <measurement group_id="O3" value="0.038" lower_limit="0.029" upper_limit="0.048"/>
                    <measurement group_id="O4" value="0.013" lower_limit="0.002" upper_limit="0.023"/>
                    <measurement group_id="O5" value="0.002" lower_limit="-0.007" upper_limit="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Hip BMD Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" lower_limit="0.001" upper_limit="0.020"/>
                    <measurement group_id="O2" value="0.031" lower_limit="0.022" upper_limit="0.040"/>
                    <measurement group_id="O3" value="0.047" lower_limit="0.038" upper_limit="0.056"/>
                    <measurement group_id="O4" value="0.021" lower_limit="0.011" upper_limit="0.030"/>
                    <measurement group_id="O5" value="-0.007" lower_limit="-0.015" upper_limit="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Week Endpoint in Wrist Bone Mineral Density (BMD)</title>
        <description>Total radius of the wrist bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).
Least squares (LS) mean values were determined using a 1-factor analysis of covariance model with treatment group as the main effect and baseline BMD as a covariate.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline total radius of the wrist BMD value.</population>
        <group_list>
          <group group_id="O1">
            <title>180 mg LY2541546 Q4W + Placebo</title>
            <description>LY2541546 + Placebo: 180 milligrams (mg) LY2541546 administered subcutaneously every 4 weeks (Q4W) for 52 weeks with Placebo administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>180 mg LY2541546 Q2W</title>
            <description>LY2541546: 180 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>270 mg LY2541546 Q2W</title>
            <description>LY2541546: 270 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>270 mg LY2541546 Q12W + Placebo</title>
            <description>LY2541546 + Placebo: 270 mg LY2541546 administered subcutaneously every 12 weeks (Q12W) with Placebo administered subcutaneously every 2 weeks when LY2541546 is not administered for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo Q2W</title>
            <description>Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint in Wrist Bone Mineral Density (BMD)</title>
          <description>Total radius of the wrist bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA).
Least squares (LS) mean values were determined using a 1-factor analysis of covariance model with treatment group as the main effect and baseline BMD as a covariate.</description>
          <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline total radius of the wrist BMD value.</population>
          <units>g/cm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" lower_limit="-0.011" upper_limit="0.001"/>
                    <measurement group_id="O2" value="-0.005" lower_limit="-0.010" upper_limit="0.001"/>
                    <measurement group_id="O3" value="-0.001" lower_limit="-0.007" upper_limit="0.005"/>
                    <measurement group_id="O4" value="-0.002" lower_limit="-0.009" upper_limit="0.004"/>
                    <measurement group_id="O5" value="-0.005" lower_limit="-0.010" upper_limit="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Week Endpoint in Bone-specific Alkaline Phosphatase (BSAP)</title>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline bone-specific alkaline phosphatase value.</population>
        <group_list>
          <group group_id="O1">
            <title>180 mg LY2541546 Q4W + Placebo</title>
            <description>LY2541546 + Placebo: 180 milligrams (mg) LY2541546 administered subcutaneously every 4 weeks (Q4W) for 52 weeks with Placebo administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>180 mg LY2541546 Q2W</title>
            <description>LY2541546: 180 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>270 mg LY2541546 Q2W</title>
            <description>LY2541546: 270 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>270 mg LY2541546 Q12W + Placebo</title>
            <description>LY2541546 + Placebo: 270 mg LY2541546 administered subcutaneously every 12 weeks (Q12W) with Placebo administered subcutaneously every 2 weeks when LY2541546 is not administered for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo Q2W</title>
            <description>Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint in Bone-specific Alkaline Phosphatase (BSAP)</title>
          <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline bone-specific alkaline phosphatase value.</population>
          <units>units/liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.000" lower_limit="-12.600" upper_limit="0.300"/>
                    <measurement group_id="O2" value="-2.000" lower_limit="-10.400" upper_limit="4.500"/>
                    <measurement group_id="O3" value="1.600" lower_limit="-4.400" upper_limit="9.800"/>
                    <measurement group_id="O4" value="-3.150" lower_limit="-10.000" upper_limit="2.900"/>
                    <measurement group_id="O5" value="-3.900" lower_limit="-11.400" upper_limit="4.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Week Endpoint in Serum Type I Collagen Fragment (CTx)</title>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline serum type I collagen fragment value.</population>
        <group_list>
          <group group_id="O1">
            <title>180 mg LY2541546 Q4W + Placebo</title>
            <description>LY2541546 + Placebo: 180 milligrams (mg) LY2541546 administered subcutaneously every 4 weeks (Q4W) for 52 weeks with Placebo administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>180 mg LY2541546 Q2W</title>
            <description>LY2541546: 180 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>270 mg LY2541546 Q2W</title>
            <description>LY2541546: 270 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>270 mg LY2541546 Q12W + Placebo</title>
            <description>LY2541546 + Placebo: 270 mg LY2541546 administered subcutaneously every 12 weeks (Q12W) with Placebo administered subcutaneously every 2 weeks when LY2541546 is not administered for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo Q2W</title>
            <description>Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint in Serum Type I Collagen Fragment (CTx)</title>
          <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline serum type I collagen fragment value.</population>
          <units>nanograms/milliliter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" lower_limit="-0.116" upper_limit="0.079"/>
                    <measurement group_id="O2" value="-0.088" lower_limit="-0.191" upper_limit="0.030"/>
                    <measurement group_id="O3" value="-0.038" lower_limit="-0.199" upper_limit="-0.009"/>
                    <measurement group_id="O4" value="-0.022" lower_limit="-0.076" upper_limit="0.029"/>
                    <measurement group_id="O5" value="0.037" lower_limit="-0.076" upper_limit="0.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Week Endpoint in Osteocalcin</title>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline osteocalcin value.</population>
        <group_list>
          <group group_id="O1">
            <title>180 mg LY2541546 Q4W + Placebo</title>
            <description>LY2541546 + Placebo: 180 milligrams (mg) LY2541546 administered subcutaneously every 4 weeks (Q4W) for 52 weeks with Placebo administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>180 mg LY2541546 Q2W</title>
            <description>LY2541546: 180 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>270 mg LY2541546 Q2W</title>
            <description>LY2541546: 270 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>270 mg LY2541546 Q12W + Placebo</title>
            <description>LY2541546 + Placebo: 270 mg LY2541546 administered subcutaneously every 12 weeks (Q12W) with Placebo administered subcutaneously every 2 weeks when LY2541546 is not administered for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo Q2W</title>
            <description>Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint in Osteocalcin</title>
          <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline osteocalcin value.</population>
          <units>micrograms/liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.087" lower_limit="-3.998" upper_limit="2.411"/>
                    <measurement group_id="O2" value="-0.764" lower_limit="-7.762" upper_limit="3.704"/>
                    <measurement group_id="O3" value="0.823" lower_limit="-3.704" upper_limit="5.116"/>
                    <measurement group_id="O4" value="-3.322" lower_limit="-5.586" upper_limit="4.822"/>
                    <measurement group_id="O5" value="-2.029" lower_limit="-6.880" upper_limit="2.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52 Week Endpoint in Serum N-terminal Extension Propeptide of Type I Collagen (P1NP)</title>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline serum N-terminal extension propeptide of type I collagen value.</population>
        <group_list>
          <group group_id="O1">
            <title>180 mg LY2541546 Q4W + Placebo</title>
            <description>LY2541546 + Placebo: 180 milligrams (mg) LY2541546 administered subcutaneously every 4 weeks (Q4W) for 52 weeks with Placebo administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>180 mg LY2541546 Q2W</title>
            <description>LY2541546: 180 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>270 mg LY2541546 Q2W</title>
            <description>LY2541546: 270 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>270 mg LY2541546 Q12W + Placebo</title>
            <description>LY2541546 + Placebo: 270 mg LY2541546 administered subcutaneously every 12 weeks (Q12W) with Placebo administered subcutaneously every 2 weeks when LY2541546 is not administered for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo Q2W</title>
            <description>Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52 Week Endpoint in Serum N-terminal Extension Propeptide of Type I Collagen (P1NP)</title>
          <population>Participants who received at least one dose of study drug with baseline and at least one post-baseline serum N-terminal extension propeptide of type I collagen value.</population>
          <units>nanograms/milliliter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.250" lower_limit="-19.300" upper_limit="1.300"/>
                    <measurement group_id="O2" value="-4.200" lower_limit="-27.200" upper_limit="6.700"/>
                    <measurement group_id="O3" value="-1.100" lower_limit="-12.800" upper_limit="10.200"/>
                    <measurement group_id="O4" value="-16.050" lower_limit="-21.700" upper_limit="0.100"/>
                    <measurement group_id="O5" value="-5.800" lower_limit="-11.550" upper_limit="5.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>180 mg LY2541546 Q4W + Placebo</title>
          <description>LY2541546 + Placebo: 180 milligrams (mg) LY2541546 administered subcutaneously every 4 weeks (Q4W) for 52 weeks with Placebo administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks.</description>
        </group>
        <group group_id="E2">
          <title>180 mg LY2541546 Q2W</title>
          <description>LY2541546: 180 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
        </group>
        <group group_id="E3">
          <title>270 mg LY2541546 Q2W</title>
          <description>LY2541546: 270 mg administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
        </group>
        <group group_id="E4">
          <title>270 mg LY2541546 Q12W + Placebo</title>
          <description>LY2541546 + Placebo: 270 mg LY2541546 administered subcutaneously every 12 weeks (Q12W) with Placebo administered subcutaneously every 2 weeks when LY2541546 is not administered for 52 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Placebo Q2W</title>
          <description>Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Spinal cord ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="11" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="15" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="31"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E3" events="19" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E5" events="16" subjects_affected="12" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood 1,25-dihydroxycholecalciferol increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Urine calcium decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Urine phosphorus decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

